Introduction
Ionotropic glutamate receptors, which include NMDA, AMPA, and kainate receptors, are ligand-gated ion channels that mediate fast excitatory neurotransmission in the CNS . NMDA receptors are involved in a myriad of neurological processes, including neuronal development and experiencedependent plasticity, but are also implicated in numerous neuropathological conditions, such as stroke, traumatic brain injury, and Alzheimer's and Parkinson's diseases (Kalia et al., 2008; Traynelis et al., 2010) . NMDA receptors are tetramers comprising two GluN1 and two GluN2 subunits (Ulbrich and Isacoff, 2007) . The GluN1 subunit is an obligate part of all NMDA receptors and is widely expressed in the CNS. By contrast, the different GluN2 subunits (GluN2A-D) have distinct temporal and spatial expression in the brain (Watanabe et al., 1992; Ishii et al., 1993; Monyer et al., 1994) . Furthermore, the different GluN2 subunits endow NMDA receptors with markedly different biophysical and pharmacological properties (Monyer et al., 1992; Vicini et al., 1998; Gielen et al., 2009; Yuan et al., 2009) .
Since the discovery of ifenprodil as a noncompetitive NMDA receptor antagonist with Ͼ500-fold selectivity for GluN2B-containing NMDA receptors (Williams, 1993) , there has been considerable focus on the development of subunit-selective antagonists for therapeutic gain (Kalia et al., 2008; Ogden and Traynelis, 2011) . Ifenprodil and related GluN2B-selective antagonists have proven to be invaluable tools to dissect the contribution of specific NMDA receptor subtypes to neurophysiological processes Hansen et al., 2010) . Despite the utility of GluN2B-selective antagonists, there has been a lag in discovery of antagonists selective for other GluN2 subunits. However, several recent reports describe novel subunit-selective ligands for GluN2C-and GluN2D-containing receptors (Costa et al., 2010; Mosley et al., 2010; Mullasseril et al., 2010; Acker et al., 2011; Hansen and Traynelis, 2011) . In addition, a new class of antagonists selective for GluN2A-over GluN2B-containing NMDA receptors was recently described (Bettini et al., 2010; McKay et al., 2011) . Inhibition of GluN1/GluN2A receptors by a compound in this class, 3-chloro-4-fluoro-N- [(4-[(2-(phenylcarbonyl) hydrazino)carbonyl]phenyl)methyl]-benzenesulfonamide (hereafter referred to as TCN-201) (see Fig. 1 A) , was surmounted by glycine, but not glutamate, suggestive of competitive inhibition at the glycine binding site. However, it remains unclear how TCN-201 inhibition can discriminate between GluN2 subunits and yet, at the same time, be surmounted by agonist binding to the GluN1 subunit.
To facilitate development of therapeutic agents, it is important to identify modulatory binding sites on the NMDA receptor. To this end, we investigated the mechanism of action for TCN-201 inhibition. We show that TCN-201 binding reduces potency of agonists at the GluN1 subunit and vice versa. We identify residues located at the dimer interface between the GluN1 and GluN2 agonist binding domains that control the subunit selectivity of inhibition. The results demonstrate that TCN-201 is a negative allosteric modulator of glycine binding and implicate the agonist binding domain interface between GluN1 and GluN2 as a putative binding site for allosteric modulators of NMDA receptors. (Bettini et al., 2010) . B, The effects of increasing concentrations of TCN-201 on responses to 100 M glutamate plus 3 M glycine from recombinant NMDA receptors expressed in Xenopus oocytes were measured using two-electrode voltage-clamp recordings. Data are from 4 -25 oocytes. C, Concentration-response data for TCN-201 inhibition of GluN1/GluN2A activated by 100 Mglutamateplusdifferentconcentrationsofglycine(1-300M).Thedataobtainedinthepresence of 300 M glycine could not be fitted to the Hill equation. Data are from 5-25 oocytes. D, Glutamate concentration-responsedataforGluN1/GluN2Acoactivatedby30Mglycineintheabsence(control) andpresenceof3MTCN-201.GlutamateEC 50 was3.6Ϯ0.2M(Nϭ8)intheabsenceofTCN-201 and 2.5 Ϯ 0.1 M (N ϭ 7) in the presence of . E, Glycine concentration-response data for GluN1/GluN2A coactivated by 100 M glutamate in the absence (0 M) and presence of increasing concentrations of . Data are from five to seven oocytes. F, A Schild plot of the glycine concentration-responsedataproducedapA 2 valueof7.53correspondingto30nMandaSchildslopeof0. 87 (95%confidenceinterval,0.83-0.92 ).G,D-Serineconcentration-responsedataforGluN1/GluN2Ain 100 M glutamate. Data are from six to eight oocytes. H, A Schild plot of the D-serine concentrationresponse data produced a pA 2 value of 7.39 corresponding to 41 nM and a Schild slope of 0.79 (95% confidence interval, 0.69 -0.89). I, D-Cycloserine concentration-response data for GluN1/GluN2A in 100 M glutamate. Data are from five to seven oocytes for each condition. J, A Schild plot of the D-cycloserine concentration-response data produced a pA 2 value of 7.39 corresponding to 41 nM and a Schild slope of 0.90 (95% confidence interval, 0.82-0.98).
composite data) were then fit to the Hill equation and plotted together with the resulting curve.
TCN-201 inhibition was evaluated using Schild plots (Arunlakshana and Schild, 1959) . The agonist EC 50 was determined in the absence of TCN-201 and EC 50 Ј determined in the presence of increasing concentrations of TCN-201. The dose ratio (DR ϭ EC 50 Ј/EC 50 ) for each concentration of TCN-201 was then calculated and log (DR Ϫ 1) was plotted versus log (TCN-201 concentration). This plot was fit with a straight line with variable slope. The slope of the Schild plot (i.e., Schild slope) is predicted to be 1 for a competitive antagonist at equilibrium according to the Schild equation: log (DR Ϫ 1) ϭ pA 2 ϩ log [B], where [B] is the TCN-201 concentration and pA 2 is the negative logarithm of the TCN-201 concentration that produces a twofold shift of the agonist EC 50 .
The allosteric constant ␣ and K b for TCN-201 inhibition were determined using a global nonlinear least-squares fitting method. All the agonist concentration-response data obtained at different TCN-201 concentrations were simultaneously fit to the following equations (Christopoulos and Kenakin, 2002) : Current responses from whole-cell voltage-clamp recordings using HEK293 cells were analyzed using ChanneLab (Synaptosoft). The deactivation time courses of the current responses were fit by two exponential components using the following equation: Unpaired t test (two-tailed) or ANOVA (one-way ANOVA with TukeyKramer posttest) was used for statistical comparisons as indicated ( p Ͻ 0.05 was considered significant). For Schild slopes, the 95% confidence intervals are calculated using the number of data points and the SE for the best fit value. All data are presented as mean Ϯ SEM.
Results

Binding of TCN-201 reduces potency of glycine at the GluN1 subunit
To assess the selectivity profile of TCN-201 across the different NMDA receptor subtypes,wedeterminedtheconcentrationeffect relationship for TCN-201 at recombinant GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, or GluN1/GluN2D receptors expressed in Xenopus oocytes using two-electrode voltage-clamp recordings. TCN-201 completely inhibited responses from GluN1/GluN2A receptors activated by 100 M glutamate plus 3 M glycine with an IC 50 value of 320 nM ( Fig. 1 B, Table 1 ). In contrast to its effects on GluN2A-containing receptors, TCN-201 did not inhibit responses from GluN2B-, GluN2C-, or GluN2D-containing NMDA receptors (Fig.  1B, Table 1 ). Moreover, TCN-201 inhibition was not affected by the presence of exon 5 in GluN1, which encodes 21 amino acids in the amino-terminal domain. GluN1-1a/ GluN2A receptors, which lack exon 5, were inhibited to 45 Ϯ 3% of control (N ϭ 7), and GluN1-1b/GluN2A receptors, which contain exon 5, were inhibited to 49 Ϯ 2% of control (N ϭ 6) by 3 M TCN-201 in the presence of 30 M glycine. In addition, 10 M TCN-201 did not affect responses activated by 100 M glutamate from GluA1 AMPA receptors (N ϭ 8) or GluK2 kainate receptors (N ϭ 10) (data not shown). Thus, TCN-201 displays strong selectivity, estimated to be Ͼ1000-fold, for GluN2A-containing NMDA receptors at a glycine concentration of 3 M.
Because TCN-201 inhibition was surmounted by high glycine concentrations (Bettini et al., 2010) , we evaluated the extent to which glycine shifts TCN-201 potency at GluN1/GluN2A by generating TCN-201 concentration-inhibition data at different concentrations of glycine (Fig. 1C, Table 1 ). In agreement with previously published observations (Bettini et al., 2010) , TCN-201 potency was reduced by increasing concentrations of glycine. For example, the IC 50 of TCN-201 was increased 16-fold from 100 nM in the presence of 1 M glycine to 1.6 M in the presence of 30 M glycine. There was no detectable inhibition of GluN1/GluN2A by 10 M TCN-201 in the presence of 300 M glycine. In a reciprocal manner, the potency of glycine at GluN1/GluN2A was reduced in the presence of increasing TCN-201 concentrations with no effects on the maximal response (Fig. 1E , Table 1 ). The EC 50 of glycine increased 100-fold from 1.5 M in the absence of TCN-201 to 150 M in the presence of 10 M TCN-201 (Table 1) . By contrast, the EC 50 of glutamate at GluN1/ GluN2A was only slightly reduced from 3.6 Ϯ 0.2 M (N ϭ 8) in the absence of TCN-201 to 2.5 Ϯ 0.1 M (N ϭ 7) in the presence of 3 M TCN-201 (Fig. 1D) . One potential interpretation of these results could be that TCN-201 is a competitive antagonist at the glycine binding site of the GluN1 subunit. However, a competitive mechanism at the GluN1 subunit would be unexpected, since TCN-201 displays a remarkable selectivity for GluN1/GluN2A over other NMDA receptor subtypes that contain different GluN2 subunits.
TCN-201 is not a competitive antagonist at the GluN1 subunit
Schild analysis is a valuable approach to determine pA 2 , an empirical measure of potency defined as the negative logarithm of the antagonist concentration that produces a twofold shift of the agonist concentration-response curves (i.e., agonist EC 50 ) (Arunlakshana and Schild, 1959; Wyllie and Chen, 2007) . For competitive antagonists, pA 2 can be considered a measure of the equilibrium constant for binding (i.e., pA 2 ϭ ϪlogK b ), and a linear fit of the Schild plot should have unitary slope (see Materials and Methods) (Arunlakshana and Schild, 1959) . However, a slope that is significantly different from 1 suggests a noncompetitive mechanism of action, such as negative allosteric modulation of agonist binding. We generated a Schild plot to evaluate the actions of TCN-201. Using the glycine EC 50 at increasing concentrations of TCN-201, we calculated a dose ratio (DR) for each antagonist concentration (see Materials and Methods). The linear fit to the data in the resulting Schild plot produced a pA 2 value of 7.53 corresponding to 30 nM and a Schild slope of 0.87, which is significantly different from 1 (95% confidence interval, 0.83-0.92) (Fig. 1 F) . Since the Schild slope is less than unity, the pA 2 value is only an estimate of ϪlogK b for TCN-201. We also evaluated the effects of TCN-201 on the potency of two other GluN1 agonists, D-serine and D-cycloserine ( Fig. 1G-J ). For both D-serine and D-cycloserine, Schild plots of the TCN-201 antagonism gave pA 2 values of 7.39 corresponding to 41 nM, similar to the pA 2 value for TCN-201 shift of glycine potency. For D-serine, the Schild slope was 0.79 (95% confidence interval, 0.69 -0.89), and for D-cycloserine, the slope was 0.90 (95% confidence interval, 0.82-0.98); in both cases, the slope was significantly different from 1. Thus, Schild plots produced slopes significantly lower than 1 for all three GluN1 agonists, suggesting that the mechanism of TCN-201 inhibition is not direct competitive antagonism between TCN-201 and GluN1 agonist at the orthosteric agonist binding site. One possible mechanism of action that can explain the observed results could be that TCN-201 is a negative allosteric modulator of agonist binding to the GluN1 subunit.
Inhibition by TCN-201 is controlled by the agonist binding domain interface
To evaluate the structural determinants of TCN-201 inhibition, we used a chimeric strategy exploiting the selectivity between GluN2A and GluN2D subunits. We first replaced the GluN2A amino-terminal domain, agonist binding domain, and transmembrane domain with homologous regions of the GluN2D subunit and evaluated inhibition by 3 M TCN-201 of the chimeric receptors activated by 100 M glutamate plus 30 M glycine (Fig. 2 A, B) . Replacing the GluN2A amino-terminal domain or transmembrane region with those of GluN2D did not reduce inhibition by . Similarly, deleting the entire aminoterminal domain of GluN2A also did not reduce inhibition by . By contrast, TCN-201 inhibition was abolished when the entire agonist binding domain of GluN2A was replaced with that of GluN2D. We further divided the agonist binding domain into segments S1 and S2 . Replacing S1 of GluN2A with that of GluN2D did not affect TCN-201 sensitivity, whereas no inhibition was observed upon replacement of S2 (Fig. 2C , Table 1 ). Consistent with this result, replacing S2 in GluN2D with that of GluN2A resulted in TCN-201 inhibition with an IC 50 of 1.6 Ϯ 0.1 M (N ϭ 6), whereas replacing S1 of GluN2D with that of GluN2A did not introduce TCN-201 sensitivity (Fig. 2 D, Table 1 ).
We subsequently divided the agonist binding domain into the upper D1 lobe of the clamshell-like structure and the lower D2 lobe (Furukawa et al., 2005) . Replacing the D1 lobe of GluN2A with that of GluN2D eliminated TCN-201 inhibition, but some TCN-201 activity was retained upon replacement of the D2 lobe (Fig. 2 B) . In these chimeric GluN2 subunits, replacement of the D1 lobe is equivalent to the combined replacement of the entire segment S1, which has no effect on TCN-201 inhibition, as well as a smaller portion of segment S2 (Fig. 2 A) . The molecular determinants of TCN-201 action could therefore be located in this smaller portion of S2, since these residues are sufficient to eliminate TCN-201 activity.
The portion of S2 that comprises the determinants of TCN-201 action differs by only 9 aa between GluN2A and GluN2D (Fig. 2 E) . We individually mutated these nine residues in GluN2A to the corresponding residues in GluN2D and found Glycine concentration-response data for GluN1/GluN2A G786D (A), GluN1/GluN2A V783L (C), GluN1/GluN2B F784V (E), and GluN1/ GluN2B L783FϩF784V (G) in the absence (0 M) and presence of increasing concentrations of TCN-201.Dataarefromfourtosixoocytes.SchildplotsforGluN1/GluN2AG786D(B),GluN1/GluN2AV783L (D), GluN1/GluN2B F784V (F), and GluN1/GluN2B L783FϩF784V (H) yield pA 2 values of 7.40, 5.67, 5.86,and6.36correspondingto40nM,2.1M,1.4M,and440nM,respectively.Forallexperiments, responses were activated by increasing concentrations of glycine plus 100 M glutamate. See that five of these mutations (GluN2A V783L, G786D, M788I, E790M, and T793R) significantly affected the inhibition by 3 M TCN-201 (Fig. 2 F) . TCN-201 concentration-inhibition data of responses activated by 100 M glutamate plus 3 M glycine confirmed effects of these five mutations on TCN-201 potency (Fig.  2G , Table 1 ). The most prominent reduction in TCN-201 potency was observed for GluN2A V783L, which was only inhibited to 70% of control by 10 M TCN-201. To evaluate potential interactions between glycine binding and TCN-201 activity on NMDA receptors containing mutant GluN2A subunits, we determined glycine EC 50 values in the absence of TCN-201. Interestingly, all of the GluN2A mutations identified by the chimeric approach affected glycine potency (Table 1) . There was significant correlation between glycine EC 50 values and values for four of the GluN2A mutants (Fig. 2 H) . Since it was not possible to reliably determine TCN-201 IC 50 for GluN2A V783L given the limits of TCN-201 solubility (see Materials and Methods), data for this mutant were not included in the test for correlation. Glycine EC 50 for NMDA receptors containing GluN2A V783L was 0.6 M, which is 1.8-fold lower than the EC 50 of 1.1 M for wild-type GluN1/GluN2A (Table 1) . Because inhibition of GluN2A V783L could not be accounted for by a shift in glycine potency, we speculate that GluN2A Val783 could be directly involved in TCN-201 binding. By contrast, the effects of the other GluN2A mutations on TCN-201 activity are primarily mediated through changes in glycine potency.
Residue Val783 in GluN2A influences binding of TCN-201
To evaluate the idea that the GluN2A V783L mutation directly affects binding of TCN-201, we used Schild plots to estimate a pA 2 value for TCN-201 potency. According to the correlation shown in Figure 2 H, only a minor change in TCN-201 binding affinity would be expected for GluN2A G786D, since the reduction of TCN-201 potency is primarily caused by an increase in glycine potency for this mutation. The Schild plot of TCN-201 antagonism on GluN2A G786D produced a pA 2 value of 7.40 corresponding to 40 nM (Fig. 3 A, B) , which is close to the 30 nM derived from the pA 2 value for wild-type GluN1/GluN2A. By contrast, the Schild plot for GluN2A V783L produced a pA 2 value of 5.67 corresponding to 2.1 M, which is 70-fold higher compared with wild-type GluN1/GluN2A (Fig. 3C,D) . These results are consistent with the idea that residue Val783 of GluN2A participates in TCN-201 binding.
If the residue in GluN2 subunits at the same position as GluN2A Val783 is an important determinant of TCN-201 binding, we predict that TCN-201 will gain some activity on GluN2B with the mutation F784V, as Phe784 in GluN2B corresponds to GluN2A Val783 (Fig. 2 E) . Indeed, TCN-201 had a pronounced effect on glycine potency of mutant GluN1/GluN2B F784V receptors and the Schild plot gave a pA 2 value of 5.86 corresponding to 1.4 M (Fig. 3 E, F ) . By contrast, glycine potency at wildtype GluN1/GluN2B was only marginally reduced in the presence of 10 M TCN-201, preventing determination of pA 2 from the Schild plot (Table 1 ). The residue immediately before GluN2A Val783 is also not conserved between GluN2A and GluN2B (Fig.  2 E) . The double mutant GluN2B L783FϩF784V, in which both of these residues are converted to the corresponding residues in GluN2A, exhibited even greater antagonism by TCN-201. The Schild plot produced a pA 2 value of 6.36 corresponding to 440 nM (Fig. 3G,H ) . Glycine EC 50 values for mutant GluN1/GluN2B L783FϩF784V in the absence of TCN-201 and in the presence 10 M TCN-201 were 0.6 Ϯ 0.1 M (N ϭ 5) and 9.5 Ϯ 0.5 M (N ϭ 6), respectively (Table 1) . TCN-201 concentration-response data for GluN1/GluN2B F784V and GluN1/GluN2B L783FϩF784V in the presence of 3 M glycine produced IC 50 values of 6.8 Ϯ 0.4 M (N ϭ 6) and 4.4 Ϯ 0.2 M (N ϭ 5), respectively (Table 1 ). In addition, TCN-201 sensitivity could also be introduced to GluN2D by a single point mutation (GluN2D L808V) at the residue corresponding to Val783 in GluN2A (72% of control at 10 M TCN-201; Table 1 ).
To further evaluate the role of residue Val783 in TCN-201 binding to GluN2A, we mutated this position to residues with Table 1 (Fig. 3) .
TCN-201 inhibition is mediated by residues from both GluN1 and GluN2A
To identify additional residues that mediate TCN-201 inhibition, we mutated residues in both GluN1 and GluN2A that are located within 8 Å of residue Val783 in GluN2A and have side chains protruding into the dimer interface according to the crystal structure of the isolated agonist binding domains from GluN1/GluN2A (Furukawa et al., 2005) (Fig. 4 A) . In GluN1, seven residues were mutated and three of these mutations affected inhibition by 3 M TCN-201 of responses to 100 M glutamate plus 30 M glycine (Fig.  4 B) . In GluN2A, 15 residues were mutated to alanine and 8 of these mutations affected TCN-201 inhibition (Fig. 4C) . To assess whether changes in TCN-201 sensitivity could be influenced by changes in glycine potency, we also determined TCN-201 IC 50 and glycine EC 50 values for the mutants (Table 1) . There was no significant correlation between glycine EC 50 values and TCN-201 IC 50 values for the GluN2A or the GluN1 mutants (Pearson's test for correlation, p Ͼ 0.05; GluN2A L780A and GluN1 R755A not included in the test). Interestingly, the GluN2A L777A and GluN2A L780A mutations markedly affected TCN-201 potency without any noticeable change in glycine potency (Fig.  4 D, Table 1 ), suggesting that these residues are involved in TCN-201 binding. Residues Leu777 and Leu780 in GluN2A are located two and one helical turns away from residue Val783 (Fig. 5) , and a previous study has implicated Leu780 in the arrangement of the agonist binding domain dimer interface, as well as in inhibition by proton and zinc (Gielen et al., 2008) . In GluN1, the F754A mutation resulted in a 6.7-fold reduction in TCN-201 IC 50 and a 2.1-fold increase in glycine EC 50 compared with wild-type GluN1/GluN2A, whereas the R755A mutation almost completely abolished TCN-201 inhibition (79% of control at 10 M TCN-201; Fig. 4 D, Table 1 ). The GluN1 R755A mutation increased both glycine EC 50 (4.0-fold) and TCN-201 IC 50 (Ͼ30-fold), suggesting a role for this residue in TCN-201 binding. Residues Phe754 and Arg755 in GluN1 are located directly opposite from Val783 in GluN2A in the dimer interface (Fig. 5) . In summary, the expanded mutagenesis identified several residues in both GluN1 and GluN2A that affect inhibition by TCN-201.
Based on evaluation of changes in TCN-201 and glycine potencies caused by the mutations, we suggest that residues Phe754 and Arg755 in GluN1, as well as Leu777, Leu780, and Val783 in Figure 5 . TCN-201 sensitivity is controlled by the agonist binding domain dimer interface between GluN1 and GluN2. A, Residues Leu777, Leu780, and Val783 of GluN2A, as well as F754 and R755 of GluN1, which substantially influence TCN-201 sensitivity, are located at the dimer interface in the crystal structure of the isolated agonist binding domains from GluN1/GluN2A with bound glutamate and glycine (PDB ID 2A5T) (Furukawa et al., 2005) . These residues are highlighted as blue spheres. GluN2A is shown in yellow, and GluN1 is shown in orange. B, The residues that influence TCN-201 sensitivity are lining part of a large water-filled cavity (ϳ5200 Å 3 ) in the dimer interface that can accommodate a modulatory binding site. The cavity was identified using the CASTp server (Dundas et al., 2006) , and the surface of the cavity is highlighted in gray. C, The side chain of GluN2A Val783 (shown as blue sticks with transparent blue spheres) is directly facing the hinge region of the bilobed GluN1 agonist binding domain. The path between GluN2A Val783 and the glycine agonist is blocked by Phe754 and Arg755 in the GluN1 hinge region. GluN2A Leu777 and Leu780 are located two and one helical turns away from Val783 in the dimer interface. The distance (C␣-C␣) between GluN2A Val783 and the glycine agonist in GluN1 is 16 Å. Selected residues important for glycine binding are shown as gray sticks, and interactions with glycine are indicated by black dashed lines.
GluN2A are important structural determinants of inhibition by TCN-201. These residues are located at the subunit dimer interface in the structure of the isolated agonist binding domains of heteromeric agonist-bound GluN1/GluN2A (Furukawa et al., 2005) (Fig. 5) . The side chain of GluN2A Val783 is directly facing the hinge region of the bilobed GluN1 agonist binding domain. Upon agonist binding, the hinge region of the agonist binding domain undergoes a conformational change that allows closure of the clamshell-like agonist binding domain around the agonist. In the GluN1/GluN2A agonist binding domain structure, GluN2A Val783 and the glycine agonist in GluN1 are separated by 16 Å (C␣-C␣ distance). However, three residues in the GluN1 hinge region (GluN1 Phe754 and Arg755, and Ser756; Fig. 5 ) lie directly between GluN2A Val783 and the agonist glycine. Interestingly, residues Phe754 and Arg755 in GluN1, as well as Leu777, Leu780, and Val783, are lining part of a large water-filled cavity (ϳ5200 Å 3 ) in the dimer interface that can accommodate a modulatory binding site (Fig. 5B) . A binding site for TCN-201 at the subunit dimer interface would be ideally positioned to allosterically couple to binding of GluN1 agonists by influencing the conformation of the agonist binding pocket and, at the same time, discriminate between GluN2 subunits by contacting GluN2 residues.
TCN-201 inhibition is mediated by a multistep mechanism
To further investigate the mechanism of action for TCN-201, we recorded whole-cell current responses under voltage clamp from recombinant GluN1/GluN2A receptors expressed in HEK293 cells. We evaluated the time course and concentration dependence of TCN-201 inhibition of steady-state responses to saturating concentrations of glutamate (50 M) and glycine (10 M) (Fig. 6) . The onset and offset of TCN-201 inhibition were adequately described by single exponential functions. Interestingly, both the time constants for inhibition ( inhibition ) and recovery from inhibition ( recovery ) were dependent on the TCN-201 concentration (Fig. 6 B, C) . Furthermore, inhibition and recovery were inversely correlated in that higher concentrations of TCN-201 that produced faster onset of inhibition also yielded a slower recovery from inhibition. The dependence of recovery on the TCN-201 concentration used to inhibit the receptor as well as the inverse correlation between inhibition and recovery are distinct from previously described properties of competitive NMDA receptor antagonists (Benveniste et al., 1990) , as well as other subunit-selective noncompetitive antagonists (e.g., Ro 8-4304, QNZ46, and DQP-1105) (Kew et al., 1998; Acker et al., 2011; Hansen and Traynelis, 2011) . Moreover, the changes in inhibition and recovery with TCN-201 concentration differ from those predicted by a bimolecular interaction for which 1/ inhibition is linearly related to the concentration of antagonist, whereas 1/ recovery is independent of antagonist concentration. Thus, the time course of action for TCN-201 modulation is incompatible with competitive inhibition and suggests a more complex mechanism of action.
TCN-201 binding is differentially modulated by glutamate and glycine binding
To determine whether binding of TCN-201 is influenced by glutamate binding or receptor activation, we performed experiments in which the receptors were preincubated with 3 M TCN-201 in the presence of either no agonist, glutamate alone (50 M), or glycine alone (10 M) immediately before activation by 50 M glutamate plus 10 M glycine. We compared responses following increasing periods of TCN-201 preincubation to control responses in the same recording before TCN-201 preincubation (Fig. 7A) . This protocol allowed us to monitor the time course of TCN-201 binding in the presence or absence of agonist. Minimal binding of TCN-201 was observed in the presence of glycine alone and inhibition could not be reliably determined (Fig. 7B) . In the absence of any agonists, the time constant for TCN-201 binding ( inhibition ) was 3.5 Ϯ 0.3 s (N ϭ 4) (Fig. 7 B, C) and was not significantly different from the inhibition value of 3.4 Ϯ 0.2 s (N ϭ 7) observed in the presence of both glutamate and glycine ( p Ͼ 0.05; one-way ANOVA with Tukey-Kramer posttest; Fig. 6 ). Interestingly, binding of TCN-201 was markedly accelerated ( inhibition ϭ 1.1 Ϯ 0.1 s; N ϭ 4) when TCN-201 was preincubated in the presence of glutamate alone (Fig. 7 B, C) . These results show that TCN-201 binding is differentially modulated by glutamate and glycine binding. Glutamate binding alone appears to shift the receptor into a conformation with increased rate of TCN-201 binding, whereas binding of glycine alone promotes a conformation with low rate of TCN-201 binding (Fig. 7D) . Receptors in the apostate (i.e., absence of agonist binding) and activated receptors The deactivation time courses of current responses following removal of 1000 M glycine in the continuous presence of 50 M glutamate plus either TCN-201 or 7-chlorokynurenic acid (7CKA) (as shown in Fig. 8 ). The deactivation time courses for brief (10 ms) glycine applications were best described using dual-exponential fits and two time constants are listed ( fast and slow ), whereas the deactivation time courses for long (5 s) glycine applications were best described using monoexponential fits and only one time constant is listed ( slow ). All values are mean Ϯ SEM.
the TCN-201 binding site or the accessibility of this site is similar for these two receptor conformations (Fig. 7D ).
TCN-201 binding accelerates glycine deactivation
These results suggest a working hypothesis in which a negative allosteric interaction exists between TCN-201 and glycine binding. To test this hypothesis, we evaluated the effects of TCN-201 on the time course of deactivation following rapid removal of glycine for recombinant GluN1/GluN2A receptors expressed in HEK293 cells. We compared deactivation with or without TCN-201 for responses to brief (10 ms) and long (5 s) applications of a high concentration of glycine (1 mM) in the continuous presence of glutamate (50 M) (Fig. 8 ). In the case of negative allosteric interaction, a brief glycine application in the presence of TCN-201 could show accelerated glycine deactivation time course compared with control, since bound TCN-201 reduces glycine potency presumably in part by increasing the microscopic dissociation rate constant. Furthermore, prolonged glycine application should result in dissociation of bound TCN-201 as glycine binding reduces TCN-201 affinity. In this scenario, the deactivation time course following prolonged agonist application will become indistinguishable from control as TCN-201 unbinds from the receptor. As predicted from this hypothesis, the weighted time constant for glycine deactivation ( weighted ) of responses to a brief glycine application was significantly reduced (i.e., glycine deactivation is accelerated by TCN-201) from 123 Ϯ 11 ms (N ϭ 6) in the absence of TCN-201 to 27 Ϯ 2 ms (N ϭ 6) in the presence of 1 M TCN-201 ( p Ͻ 0.05; one-way ANOVA with Tukey-Kramer posttest) ( Fig. 8B, F; see Table 2 for fast and slow values). Acceleration of glycine deactivation by demonstrates that activated NMDA receptors can simultaneously bind glycine and TCN-201, and again is incompatible with a competitive mechanism of action for TCN-201. For prolonged application of glycine in the presence of TCN-201, we observed a rapidly rising current response followed by a slower increase to steady state that reflects additional glycine binding and resulting TCN-201 dissociation subsequent to a reduction of TCN-201 affinity (Fig. 8C) . Since prolonged application of glycine results in complete unbinding of TCN-201 under these experimental conditions, there was no significant difference between weighted for glycine deactivation of responses to a long glycine application in the presence or absence of TCN-201 (Fig. 8D,F) .
In contrast to negative allosteric modulation of glycine binding, the time course of glycine deactivation should be unaffected by a glycine site competitive antagonists, since it is not possible for glycine and the competitive antagonist to simultaneously bind to activated NMDA receptors. As expected, the competitive glycine site antagonist 7,5-dichlorokynurenic acid (DCKA) (0.3 M) did not alter the deactivation time course for either brief (10 ms) or long (5 s) applications of 1 mM glycine in the continuous presence of 50 M glutamate compared to control in the absence of DCKA (Fig. 8B,D,F) . DCKA inhibited the peak response to a brief glycine application to 43 Ϯ 13% of control (N ϭ 6) ( Fig.  8A,E) .
TCN-201 is a negative allosteric modulator of glycine binding
A straightforward model for allosteric modulation of agonist binding without any change in agonist efficacy is shown in Figure  9A . In this model, the dissociation constant for agonist binding (K a ) is changed by a factor of 1/␣ upon binding of the allosteric modulator, where ␣ is the allosteric constant (Ehlert, 1988; Christopoulos and Kenakin, 2002) . Similarly, the dissociation constant for modulator binding (K b ) is changed by a factor 1/␣ upon agonist binding. We assume that agonist efficacy E is not changed by modulator binding, which renders the inhibition fully surmountable by increased concentrations of agonist. Positive allosteric modulation is achieved if ␣ Ͼ 1 and negative modulation is achieved if ␣ Ͻ 1. Figure 9A also shows the relationship describing the dose ratio DR (i.e., the ratio of agonist EC 50 values in presence and absence of modulator EC 50 Ј/EC 50 ) as a function of the modulator concentration [B] , modulator binding affinity K b , and the allosteric constant ␣ (Ehlert, 1988; Christopoulos and Kenakin, 2002) . From this, it can be seen that this type of allosteric modulation is saturable, meaning that an infinite concentration of modulator B will maximally shift the agonist EC 50 Ј value to EC 50 /␣. In addition, it can be seen that, if ␣ ϭ 0, the model in Figure 9A reduces to a competitive mechanism and the relationship becomes the Schild equation. In the case of negative allosteric modulation by TCN-201, we predict that the allosteric constant ␣ will be close to 0 and that binding affinity will be close to the pA 2 value obtained in the Schild plot shown in Figure 1 F.
To determine ␣ and K b for TCN-201 inhibition of GluN1/ GluN2A, we reanalyzed the glycine concentration-response data shown in Figure 1 E by simultaneously fitting the relationship shown in Figure 9A to all of the data using a global nonlinear regression method (Christopoulos and Kenakin, 2002 ) (see Materials and Methods). This analysis gave a K b value of 45 nM and an allosteric constant ␣ of 0.0025 (Fig. 9B) . The allosteric constant ␣ ϭ 0.0025 implies that TCN-201 can maximally cause a 400-fold (i.e., 1/␣) increase in glycine EC 50. Since glycine EC 50 is 1.1 M in the absence of TCN-201, an infinite concentration of TCN-201 will increase glycine EC 50 to 440 M. However, TCN-201 concentrations well above the limit of solubility, estimated to be 18 M, would be required to maximally shift the glycine EC 50 . In fact, the K b of 45 nM for TCN-201 in the absence of glycine is predicted to increase 400-fold to 18 M in the presence of an infinite concentration of glycine. Figure 9C illustrates the effect of different values for the allosteric constant ␣ on the Schild plot for negative allosteric modulators with K b ϭ 45 nM.
Discussion
The results from this study suggest that a binding site for allosteric modulators of NMDA receptor exists at the dimer interface between the GluN1 and GluN2 agonist binding domains. The dimer interface between agonist binding domains of AMPA receptor subunits is a well described binding site for allosteric modulation (Sun et al., 2002; Jin et al., 2005; Hald et al., 2009; Ptak et al., 2009; Ahmed et al., 2010) , and positive allosteric modulators of AMPA receptor function are currently being evaluated for the treatment of depression and attention deficit/hyperactivity disorder (ADHD), as well as for the improvement of cognitive deficits in Alzheimer's disease (Ward et al., 2010) . Allosteric AMPA receptor modulators enhance receptor function by reducing desensitization and/or by slowing deactivation of the receptor response. Similarly, it has been shown that Na ϩ and Cl Ϫ ions bind and stabilize the dimer interface in kainate receptors to attenuate desensitization (Wong et al., 2006 (Wong et al., , 2007 Plested and Mayer, 2007; Plested et al., 2008) and that Ca 2ϩ ions stabilize the dimer interface of the structurally related glutamate-like receptor GluD2 (Naur et al., 2007; Hansen et al., 2009) . By contrast, modulators that bind the dimer interface between the agonist binding domains of GluN1 and GluN2 in NMDA receptors have not been described before this study. This GluN1-GluN2 dimer interface buries ϳ2600 Å of solvent-accessible surface area and harbors a large water-filled pocket that can accommodate a modulatory binding site (Furukawa et al., 2005) (Fig. 5) .
The data presented here provide multiple lines of evidence to suggest that TCN-201 is a negative allosteric modulator of glycine binding to the GluN1 subunit of NMDA receptors. First, TCN-201 binding reduces glycine potency and vice versa (Fig. 1C,E) . Second, the Schild slope was significantly lower than unity, indicating TCN-201 is not a competitive antagonist (Fig. 1 F) . Third, the rates of inhibition and recovery depended on the TCN-201 concentration in a manner that is incompatible with a competitive mechanism of action (Fig. 6) . Finally, TCN-201 and glycine can simultaneously bind activated NMDA receptors, resulting in acceleration of glycine deactivation (Fig. 8) . This mechanism of TCN-201 action is strikingly different from those of compounds or ions that bind to and stabilize the agonist binding domain interface of AMPA and kainate receptors.
The allosteric constant ␣ has been used to describe the effectiveness of allosteric modulators of G-protein-coupled receptors (Lazareno and Birdsall, 1995; Schetz and Sibley, 1997; Hedlund et al., 1999) . We estimated the allosteric constant ␣ for TCN-201 to be 0.0025, which results in inhibition that is difficult to distinguish from a competitive mechanism of action. The small allosteric constant ␣ prevented us from observing saturation of the increase in glycine EC 50 at the TCN-201 concentrations evaluated here. It was therefore not possible to determine whether TCN-201 modulates agonist efficacy (i.e., NMDA receptor gating) in addition to its effects on glycine binding. This distinction would require functional data at saturating concentrations of both glycine and TCN-201 to eliminate allosteric effects on binding; however, the solubility of TCN-201 precludes this determination. For comparison, the allosteric GluN2B subunit-selective modulator ifenprodil increases potency of GluN2 agonists, such as NMDA and glutamate, but at the same time reduces agonist efficacy (Kew et al., 1996; Zhang et al., 2000) . Since allosteric interactions are reciprocal, the GluN2 agonists also increase potency of ifenprodil.
Studies that seek to understand the structure-activity relationship of allosteric modulators at the TCN-201 binding site could potentially identify ligands with different subunit selectivity and mechanism of action (e.g., allosteric modulation of glutamate binding). Moreover, compounds acting at the TCN-201 binding site seem capable of achieving considerable subunit selectivity, as demonstrated by the Ͼ1000-fold selectivity of TCN-201 for GluN1/GluN2A over other NMDA receptor subtypes. The characterization of TCN-201 inhibition described here reveals previously unrecognized features of NMDA receptor structure and function, and provides compelling data suggesting that novel allosteric regulators of NMDA receptor function exist with high subunit selectivity. Such compounds could provide an opportunity for the development of new pharmacological tools and therapeutic agents with novel mechanisms underlying their subunit selectivity.
